Amgen Testing Whether Different Is Better In Obesity, With Data Due This Year
GIP Receptor Antagonism Versus Agonism On Trial
Amgen’s obesity drug MariTide will not have Phase II results until late 2024, but the company’s Q4 earnings call was dominated by questions seeking insight about the drug’s potential.
